BI's Praxbind US Approval May Boost Pradaxa Sales

The FDA on Oct. 16 gave privately held Boehringer Ingelheim GmgH the go-ahead to market its humanized monoclonal antibody fragment Praxbind (idarucizumab) under an accelerated approval as an agent to reverse the blood-thinning effects of the company's highly popular anticoagulant Pradaxa (dabigatran) in emergency surgery or urgent procedures or in situations when there's life-threatening or uncontrolled bleeding.

The FDA on Oct. 16 gave privately held Boehringer Ingelheim GmgH the go-ahead to market its humanized monoclonal antibody fragment Praxbind (idarucizumab) under an accelerated approval as an agent to reverse the blood-thinning effects of the company's highly popular anticoagulant Pradaxa (dabigatran) in emergency surgery or urgent procedures or in situations when there's life-threatening or uncontrolled bleeding.

Praxbind is the first drug available in the US to reverse Pradaxa, a direct thrombin inhibitor indicated in the US to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, to treat deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cardiovascular

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Copycats Compound Novo’s Wegovy Growth Problems

 

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Merck & Co. CMO Eliav Barr Assures On Pipeline As Keytruda LOE Looms Large

 

Chief medical officer Eliav Barr, responsible for overseeing clinical development, talked to Scrip in an interview at Merck’s headquarters about the company’s pipeline diversification.

CNS, Cardiometabolics A Bright Spot In Recent Chinese VC/PE Fundings

 

Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By 

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.